Depression in Parkinson's disease

Journal of Neurology

Volumn 254, Issue SUPPL. 5, 2007, Pages 49-55

  Poewe, Werner ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Anhedonia; Antidepressants; Depression; Dopamine agonists; Parkinson's disease

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; DESIPRAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PERGOLIDE; PLACEBO; PRAMIPEXOLE; REBOXETINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANHEDONIA; ANXIETY; APATHY; CLINICAL FEATURE; CONFERENCE PAPER; COUNSELING; DEMENTIA; DENERVATION; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOPAMINERGIC NERVE CELL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; HUMAN; LIMBIC SYSTEM; NEUROTRANSMISSION; NONHUMAN; NORADRENERGIC NERVE; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSIS; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; SLEEP WAKING CYCLE; SYMPTOM; TREATMENT OUTCOME;

EID: 34548742956     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-007-5008-4     Document Type: Conference Paper

References (46)

1. th edition. First MB, Wipliger TA (eds)
2. Andersen J, Aabro E, Gulmann N, Hjelmsted A, Pedersen J (1980) Antidepressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-dopa. Acta Neurol Scand 64:210-219
3. Avila A, Cardona X, Martin-Baranera M, Maho P, Sastre F, Bello J (2003) Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial. J Clin Psychopharmacol 23:509-513
4. Barone P, Goetz C, Houben J, Koester J, Leentjens A, Poewe W, Rascol O, Reichmann H, Schapira A, Tolosa E (2006) PRODEST - Depression symptoms in Parkinson's disease (Abstract). MDS Congress, Kyoto
5. Barone P, Scarzella L, Marconi R, Antonini A, Morgante L, Bracco F, Zappia M, Musch B; Depression/Parkinson Italian Study Group (2006) Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol 253:601-607
6. Bayulkem K, Torun F (2002) Therapeutic efficiency of venlafaxin in depressive patients with Parkinson's disease. Mov Disord 17(Suppl 5):204
7. Bejjani B, Damier P, Arnulf I, Thivard L, Bonnet A, Dormont D, Cornu P, Pidoux B, Samson Y, Agid Y (1999) Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med 340:1476-1480
8. Braak H, del Tredici K, Rub U, De Vos RAI, Jansen Steur ENH, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211
9. Ceravolo R, Nuti A, Piccinni A, Dell'Agnello G, Bellini G, Gambaccini G, Dell'Osso L, Murri L, Bonuccelli U (2000) Paroxetine in Parkinson's disease: effects on motor and depressive symptoms. Neurology 55:1216-1218
10. Corrigan M, Denahan A, Wright C, Ragual R, Evans D (2000) Comparison of pramipexole, fluoxentine and placebo in patients with major depression. Depress Anxiety 11:58-65
11. Cummings JL (1992) Depression and Parkinson's disease: a review. Am J Psychiatry 149:443-454
12. Damier P, Hirsch EC, Agid Y, Graybiel AM (1999) The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122:1437-1448
13. Doder M, Rabiner EA, Turjanski N (2000) Brain serotonin 1A receptors in Parkinson''s disease with and without depression measured by positron emission tomography with 11C-WAY 100635 (Abstract). Mov Disord 15:213
14. Forno LS (1982) Pathology of Parkinson's disease. In: Marsden CD, Fahn S (eds) Movement Disorders, Neurology 2. Butterworths International Medical Reviews pp 25-40
15. Fregni F, Santos CM, Myczkowski ML, Rigolino R, Gallucci-Neto J, Barbosa ER, Valente KD, Pascual-Leone A, Marcolin MA (2004) Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 75:1171-1174
16. Gibb W, Lees A (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 51:745-752
17. Goetz CG, Koller WC, Poewe W, Rascol O, Sampaio C; on behalf of the MDS Task Force (2002) Management of Parkinson's disease: an evidence based review. Mov Disord 17:Suppl 4
18. Gonera E, van't Hof M, Berger H, van Weel C, Horstink M (1997) Symptoms and duration of the prodromal phase in Parkinson's disease. Mov Disord 12:871-876
19. Hely MA, Morris JG, Reid WG, Trafficante R (2005) Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 20:190-199
20. Jouvent R, Abensour P, Bonnet AM (1983) Antiparkinsonian and antidepressant effects of high doses of bromocriptine: an independent comparison. J Affect Disord 5:141-145
21. Krack P, Kumar R, Ardouin C, Dowsey P, McVicker J, Benabid A, Pollak P (2001) Mirthful laughter induced by subthalamic nucleus stimulation. Mov Disord 16:867-875
22. Leentjens A, Van den Akker M, Metsemakers J, Lousberg R, Verhey F (2003) Higher incidence of depression preceding the onset of Parkinson's disease: a register study. Mov Disord 18:414-418
23. Leentjens AF, Vreeling FW, Luijeckx GJ, Verhey FR (2003) SSRIs in the treatment of depression in Parkinson's disease. Int J Geriatr Psychiatry 18:552-524
24. Lees AJ, Shaw KM, Kohout LJ, Stern GM (1977) Deprenyl in Parkinson's disease. Lancet 15:791-795
25. Lemke MR (2002) Effect of reboxetine on depression in Parkinson's disease patients. J Clin Psychiatry 63:300-304
26. Maricle RA, Nutt JG, Carter JH (1995) Mood and anxiety fluctuation in Parkinson's disease associated with levodopa infusion: preliminary findings. Mov Disord 10:329-332
27. Mayeux R, Stern Y, Sano M, Williams JB, Cote LJ (1988) The relationship of serotonin to depression in Parkinson's disease. Mov Disord 3:237-244
28. Meara J, Bhowmick BK, Hobson P (1999) Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 28:99-102
29. Okabe S, Ugawa Y, Kanazawa I; Effectiveness of rTMS on Parkinson's Disease Study Group (2003) 0.2-Hz repetitive transcranial magnetic stimulation has no add-on effects as compared to a realistic sham stimulation in Parkinson's disease. Mov Disord 18:382-388
30. Okun M, Watts R (2002) Depression associated with Parkinson's disease: clinical features and treatment. Neurology 26(Suppl 1):S63-S70
31. Poewe W, Granata R, Geser F (2004) Pharmacological treatment of Parkinson's disease. In: RL Watts, WC Koller (eds) Movement Disorders, Neurologic Principles and Practice. McGraw-Hill, New York, pp 247-271
32. Rektorová I, Rektor I, Bares M, Dostál V, Ehler E, Fanfrdlová Z, Fiedler J, Klajblová H, Kulit'ák P, Ressner P, Svátová J, Urbánek K, Velísková J (2003) Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 10:399-406
33. Remy P, Doder M, Lees A, Turjanski N, Brooks D (2005) Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128:1314-1322
34. Richard I, Kurlan R (1997) A survey of antidepressant drug use in Parkinson's disease. Parkinson Study Group. Neurology 49:1168-1170
35. Richard IH (2006) Apathy does not equal depression in Parkinson disease: why we should care. Neurology 67:33-38
36. Sano M, Stern Y, Williams J, Cote L, Rosenstein R, Mayeux R (1989) Coexisting dementia and depression in Parkinson's disease. Arch Neurol 46:1284-1286
37. Santamaria J, Tolosa E, Valles A (1986) Parkinson's disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology 36:1130-1133
38. Schrag A, Jahanshahi M, Quinn N (2000) What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 69:308-312
39. Shulman LM, Taback RL, Bean J, Weiner WJ (2001) Comorbidity of the nonmotor symptoms of Parkinson's disease. Mov Disord 16:507-510
40. Starkstein SE, Mayberg HS, Leiguarda R, Preziosi TJ (1992) A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 55:377-382
41. Steur EN, Ballering LA (1997) Moclobemide and selegiline in the treatment of depression in Parkinson's disease. J Neurol Neurosurg Psychiatry 63:547
42. Tandberg E, Larsen JP, Aarsland D, Cummings JL (1996) The occurrence of depression in Parkinson's disease. A community-based study. Arch Neurol 53:175-179
43. Tesei S, Antonini A, Canesi M, Zecchinelli A, Mariani CB, Pezzoli G (2000) Tolerability of paroxetine in Parkinson's disease: a prospective study. Mov Disord 15:986-989
44. Weintraub D, Morales KH, Moberg PJ, Bilker WB, Balderston C, Duda JE, Katz IR, Stern MB (2005) Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord 20:1161-1169
45. Weisskopf M, Chen H, Schwarzschild M, Kawachi I, Ascherio A (2003) Prospective study of phobic anxiety and risk of Parkinson's disease. Mov Disord 18:646-651
46. Wermuth L, Sorensen P, Timm S, Christensen B,Utzon N, Boas J, Dupont E, Hansen E Magnussen I, Nikkelsen B, Worm-Petersen J, Lauritzen L, Bayer L, Bech P (1998) Depression in idiopathic Parkinson's disease treated with citalopram. Nord J Psychiatry 52:163-169